The screening of candidate targets in NGF-treated osteosarcomas revealed that the NGF-induced upregulation of VCAM-1 was more pronounced than that of ICAM-1 or CCL2 (Fig. 2A). This evidence concerns the gene CCL2 and osteosarcoma.